User login
Key clinical point: Stereotactic body radiation therapy (SBRT) is safe and shows low incidence of high-grade bleeding in older patients with localized prostate cancer who received anticoagulant or antiplatelet treatment.
Major finding: Overall, 18.2% of patients reported hematuria with a median time of 10.5 months and 38.6% experienced hematochezia with a median time of 6 months. Rates of grade 2 or more hematuria and hematochezia were 4.6% and 2.5%, respectively. No grade 4 or 5 toxicities were reported.
Study details: A retrospective study of 44 patients with localized prostate cancer (median age, 72 years) who were treated with SBRT between 2007 and 2017 and received anticoagulant or antiplatelet at baseline. Patients with rectal spacer were not included.
Disclosures: The study was funded by Accuray, National Institute on Minority Health and Health Disparities and The James and Theodore Pedas Family Foundation. The authors did not declare any conflict of interests.
Source: Pepin A et al. Front Oncol. 2021 Sep 17. doi: 10.3389/fonc.2021.722852.
Key clinical point: Stereotactic body radiation therapy (SBRT) is safe and shows low incidence of high-grade bleeding in older patients with localized prostate cancer who received anticoagulant or antiplatelet treatment.
Major finding: Overall, 18.2% of patients reported hematuria with a median time of 10.5 months and 38.6% experienced hematochezia with a median time of 6 months. Rates of grade 2 or more hematuria and hematochezia were 4.6% and 2.5%, respectively. No grade 4 or 5 toxicities were reported.
Study details: A retrospective study of 44 patients with localized prostate cancer (median age, 72 years) who were treated with SBRT between 2007 and 2017 and received anticoagulant or antiplatelet at baseline. Patients with rectal spacer were not included.
Disclosures: The study was funded by Accuray, National Institute on Minority Health and Health Disparities and The James and Theodore Pedas Family Foundation. The authors did not declare any conflict of interests.
Source: Pepin A et al. Front Oncol. 2021 Sep 17. doi: 10.3389/fonc.2021.722852.
Key clinical point: Stereotactic body radiation therapy (SBRT) is safe and shows low incidence of high-grade bleeding in older patients with localized prostate cancer who received anticoagulant or antiplatelet treatment.
Major finding: Overall, 18.2% of patients reported hematuria with a median time of 10.5 months and 38.6% experienced hematochezia with a median time of 6 months. Rates of grade 2 or more hematuria and hematochezia were 4.6% and 2.5%, respectively. No grade 4 or 5 toxicities were reported.
Study details: A retrospective study of 44 patients with localized prostate cancer (median age, 72 years) who were treated with SBRT between 2007 and 2017 and received anticoagulant or antiplatelet at baseline. Patients with rectal spacer were not included.
Disclosures: The study was funded by Accuray, National Institute on Minority Health and Health Disparities and The James and Theodore Pedas Family Foundation. The authors did not declare any conflict of interests.
Source: Pepin A et al. Front Oncol. 2021 Sep 17. doi: 10.3389/fonc.2021.722852.